Enliven Therapeutics reported that its experimental drug triggered molecular responses in nearly half of patients battling advanced leukemia. The findings, presented in a new study, offer a potential new option for patients with limited alternatives.
The drug is designed to target specific genetic drivers of the cancer, a strategy that has reshaped oncology in recent years. Success in this heavily pretreated population suggests the therapy may address a significant unmet medical need.
According to the study, nearly half of participants achieved a molecular response, a benchmark that typically correlates with improved survival. The data were released by the company but not yet peer-reviewed.
If confirmed in larger trials, the therapy could become a critical tool for leukemia patients resistant to existing treatments. The company is expected to discuss next steps with regulators in the coming months.
Analysts caution that early-stage results often fail to replicate in larger studies. The durability of these responses remains unclear without longer follow-up.